Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
October 28, 2020Targovax announces formation of new Scientific Advisory Board
October 26, 2020Targovax ASA: Invitation to presentation of Targovax’s third quarter 2020 results, Thursday 5 November
October 22, 2020TARGOVAX ASA – REGISTRATION OF SHARE CAPITAL INCREASE FOLLOWING THE PRIVATE PLACEMENT
October 20, 2020TARGOVAX ASA – NO SUBSEQUENT OFFERING